1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The National Institutes of Health is the world's largest public funder of biomedical research, with a $47 billion annual budget distributed across 27 institutes and centers. Each institute has its own mission, payline, and review culture — a successful R01 at NIGMS looks different from one at NCI or NIMH. Understanding these differences is the first step toward a funded application.
NIH organizes its grants by activity code. R01s ($250K-$500K per year for 3-5 years) are the primary mechanism for investigator-initiated research and represent the majority of the extramural portfolio. R21 Exploratory/Developmental grants ($275K total over two years) fund early-stage projects. K-series career development awards support investigators at various career stages, from K08 mentored clinical scientist awards to K99/R00 pathway-to-independence grants for postdocs.
Success rates and paylines vary substantially by institute. Overall NIH success rates hover around 20-23%, but specific institutes range from 12% (NCI) to over 30% (NIGMS for certain mechanisms). Receipt dates follow a standard three-cycle calendar — February/March, June/July, and October/November — though many program announcements have their own deadlines. SBIR/STTR grants through NIH have notably higher success rates, often exceeding 20%.
Use Granted to search across all 27 institutes simultaneously, filtering by mechanism, institute, and deadline. Our NIH success rate data helps you target institutes and mechanisms where your research has the strongest chance of funding.
R01 Research Project ($250K-$500K/yr)
The gold-standard investigator-initiated grant supporting a discrete project for 3-5 years. Modular budgets up to $250K/yr or detailed budgets for larger awards.
R21 Exploratory ($275K total)
Two-year exploratory grants for novel ideas that lack preliminary data. Lower funding but faster turnaround. No renewal possible — designed as a stepping stone to R01.
K99/R00 Pathway to Independence
Up to 5 years total: 1-2 years mentored postdoctoral (K99) plus 3 years independent (R00). Explicitly designed to help postdocs transition to faculty positions.
NIH SBIR (20%+ success rate)
Small Business Innovation Research grants through NIH institutes. Phase I up to $275K, Phase II up to $1.75M. Higher success rates than academic R01s for strong applications.
Browse grants →Notice of Intent to Publish a Funding Opportunity Announcement for Impact of Technology and Digital Media Exposure Usage on Child and Adolescent Development is sponsored by National Institutes of Health (NIH) - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This NOFO will solicit applications for research on the impact of technology and digital media on children and adolescents, including potential broader effects on their families and communities.
Impact of Technology and Digital Media Exposure Usage on Child and Adolescent Development is sponsored by National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This Notice of Funding Opportunity (NOFO) will solicit applications for research on the impact of technology and digital media (TDM) on children and adolescents, including potential broader effects on their families and communities. TDM encompasses social media, applications, websites, AI, mobile devices, video games, virtual reality, and other media technologies. The goal is to understand how TDM use and exposure impacts children's health and development and alters interactions between children, family members, peers, and society.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs is sponsored by Various Federal Agencies (e.g., SBA, NIH, DOE, DOD, NSF). These competitive federal grant programs provide funding opportunities for small businesses to perform research and development (R&D) on technology of interest to federal agencies. They encourage scientific research with high potential for commercialization.
212 matching grants · showing 30
NIH NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) is a grant from the National Institutes of Health (NIH) / National Cancer Institute (NCI) that funds early-stage postdoctoral researchers in cancer-related fields to transition to independent research careers. The award provides a mentored phase (K99) followed by an independent phase (R00), supporting investigators who do not require an extended period of supervised training beyond their doctoral degrees. Eligible applicants must hold a research or clinical doctoral degree and be postdoctoral fellows who have not yet established independent research careers. The March 11, 2026 due date applies; award amounts vary by project.
NIH R25 Summer Research Education Experience Program is a grant from the National Institutes of Health (NIH) that funds universities and institutions of higher education to provide summer research experiences in environmental health sciences to high school students, college undergraduates, and science teachers. Administered through the National Institute of Environmental Health Sciences (NIEHS), the program aims to attract young people to scientific careers and help teachers communicate about the scientific process more effectively. Eligible applicants are U.S. institutions eligible for NIH grants. The application deadline was March 17, 2026.
Mobile Health (mHealth): Technology and Outcomes in Low and Middle Income Countries is a grant from the Fogarty International Center at NIH that funds research on mobile health technologies and their outcomes in low and middle income countries. Administered as an R21/R33 Phased Innovation Award, this funding opportunity supports studies that leverage mHealth tools to address health challenges in resource-limited settings. Participating NIH components include FIC, NEI, NIBIB, NICHD, NIDCD, NIMH, and NCI. Applications must align with the mission of the participating institutes. The program accommodates clinical trial optional designs. Award amounts vary by application and institute. The deadline for the most recent cycle was March 20, 2026.
The NIA Academic Leadership Career Award (K07, No Independent Clinical Trial) is a career development award from the National Institute on Aging (NIH) that supports established investigators who want to expand their expertise in aging-related research and academic leadership. Awards provide up to $150,000 per year to fund protected research and mentoring time. Eligible applicants are investigators with a doctoral degree (PhD, MD, or equivalent) who are named PD/PI on an active R01 or equivalent NIA grant, devote 25-50% full-time professional effort to the award, and are U.S. citizens or permanent residents. The application deadline is March 20, 2026.
NIH HEAL Initiative Funding Opportunities is sponsored by National Institutes of Health (NIH). The NIH HEAL Initiative accelerates scientific solutions to address the national overdose crisis, including opioid and stimulant use disorders and pain. It encompasses prevention, treatment, and recovery support approaches across the lifespan. Various funding opportunities are available for research in these areas.
The FDT-BioTech program is a joint NSF NIH and FDA initiative that catalyzes biomedical technological innovation through foundational development of methods and algorithms relevant to digital twins and synthetic humans. The program supports inherently interdisciplinary research projects that underpin the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications with a particular focus on digital in silico models used in the evaluation of medical devices and to advance regulatory sciences. Priority research areas include computational representations of physiological systems verification validation and uncertainty quantification transferability and generalizability across populations ethics security and privacy considerations and validation mechanisms for digital twin models. The program incorporates AI and machine learning as key enabling technologies for creating responsive digital twin models. All proposals must address regulatory science benefits and ethical implications. This program is distinct from the NSF SCH Smart Health program which focuses broadly on AI for health research and from ARPA-H programs which target specific clinical applications.
Notice of Special Interest (NOSI): Encouraging Women's Health Research within the NIDCD Mission Areas is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD) / National Institutes of Health (NIH). This notice solicits grant applications seeking to improve women's health across the lifespan within the scope of NIDCD's mission.
LAUNCH Program is sponsored by National Institutes of Health (NIH). The LAUNCH program supports the training of future global health researchers by providing early career researchers in the U.S. an opportunity for immersion in the wide-ranging health conditions and challenges experienced in international low-resource settings and to partner with local health researchers.
NLM Information Resource Grants to Reduce Health Disparities and Promote Health for All (G08 Clinical Trial Not Allowed) is sponsored by National Library of Medicine (NIH). This funding opportunity supports the development of information resources and services that provide accurate health information to populations experiencing health disparities and their providers, to improve health literacy, decision-making, and reduce disparities.
Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed) is sponsored by National Institutes of Health (NIH). This grant supports the development of broad-impact human health and disease models and resources for biomedical research, applicable across multiple NIH institutes.
BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18 - Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). Supports preclinical studies to demonstrate proof of concept for novel recording and modulation technologies in the human central nervous system.
Notice of Special Interest (NOSI): Administrative Supplements for Research on Women's Health in Low- and Middle-Income Countries (LMICs) is sponsored by Office of Research on Women's Health (ORWH), National Institutes of Health (NIH). This NOSI announces the availability of administrative supplements to existing NIH grants to support research on women's health in LMICs. This could include research on women's health cancers within the scope of an existing grant.
Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historically Black Colleges and Universities (RFA-EB-26-003) is sponsored by National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB). This Notice of Funding Opportunity (NOFO) solicits applications to enhance bioengineering and imaging research capacity, technology innovation, education and research training, and opportunities for scientific growth at Historically Black College and Universities (HBCUs).
The NCI Informatics Technology for Cancer Research (ITCR) program funds research-driven informatics technology development to address critical needs across cancer research, including machine learning and statistical methods, natural language processing and text mining, analytics and visualization platforms, clinical decision support tools, and interactive modeling environments. ITCR supports tools across the full development lifecycle and requires that funded software be open-source and freely available to academic and nonprofit researchers. AI and machine learning are central emphases, with awardees expected to collaborate across the ITCR network and participate in annual meetings. Multiple RFAs and announcements are issued across innovative, early-stage, advanced development, and sustainment stages.
Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation systems. Instruments supported include, but are not limited to, light microscopes, biomedical imagers, mass spectrometers, nuclear magnetic resonance spectrometers, flow cytometers, DNA and protein sequencers, biosensors, and X-ray diffractometers. Confocal microscopes are explicitly mentioned as a supported instrument type. Applications for more than one type of instrument are not responsive to this NOFO. Awards are for one year and do not allow indirect costs.
Novel Experiential Technologies Assisting Individual Learning Hubs (NExT AI Hubs) is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) - NIH. This initiative seeks to advance NICHD's mission through a Centers program that will carry out research on understudied, highly innovative, and high-risk research topics related to the impact of Artificial Intelligence (AI) technologies on developmental outcomes in children at r…
Novel Experiential Technologies Assisting Individual learning Hubs (NExT AI Hubs) is sponsored by National Institutes of Health (NIH) / Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This Centers program seeks research on understudied, highly innovative, and high-risk topics related to the impact of Artificial Intelligence (AI) technologies on developmental outcomes in children at risk for, or diagnosed with, specific learning disabilities (SLD) impacting re…
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). This funding opportunity invites investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically GLP-1 or dual GLP-1/GIP-1 receptor agonists, impact cancer risk. The focus includes reported effects on thyroid, prostate, and other cancer risks. The NOFO also aims to attract scientists from other fields to study incretin mimetic effects on cancer biology.
Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional) is sponsored by U.S. Department of Health and Human Services; National Library of Medicine; National Institutes of Health (NIH). This program supports innovative, scalable bioinformatics research with broad biomedical impact. This can include AI applications within bioinformatics, translational bioinformatics, and computational biology.
Research Grants in Clinical Informatics (R01 Clinical Trial Optional) is sponsored by U.S. Department of Health and Human Services, National Institutes of Health (NIH). This NIH funding opportunity supports innovative clinical informatics research to transform health data into actionable knowledge. While broad, it can include projects leveraging AI for data analysis and integration to advance biomedical research.
Research Council of Finland (RCF) – National Institutes of Health (NIH) Partnership Program (PA-26-085) is sponsored by NIH Fogarty International Center. This program funds collaborative health research projects between U.S. and Finnish universities. While not explicitly focused on traditional medicine or complementary health, research in global health could be part of the collaborative projects.
NIHCM Grants are investigator-initiated policy research grants from the National Institute for Health Care Management (NIHCM) that fund solutions-oriented studies improving U.S. healthcare affordability, accessibility, and quality. The 2026-2027 cycle prioritizes research on rising healthcare spending, consolidation, AI in healthcare, prescription drugs, rural health, and maternal health. NIHCM is making $500,000 available this cycle with most grants in the $50,000 range. Letters of inquiry are due June 8, 2026; full proposals invited in August, with award notifications in December 2026.
Pre-application: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System (OT1) (RFA-RM-16-002) is sponsored by National Institutes of Health (NIH). This funding opportunity invites pre-applications for SPARC Technologies to Understand the Control of Organ Function by the Peripheral Nervous System. It's a required first step for those interested in submitting a full application to the companion OT2 FOA (RFA-RM-16-003). The SPARC program aims to provide a scientific foundation for neuromodulation devices and stimulation protocols.
Institutional Mentored Career Development Award (K12) is sponsored by National Institutes of Health (NIH). This program supports institutional career development awards designed to prepare newly trained clinicians who have made a commitment to independent research careers and to facilitate their transition to more advanced support mechanisms, such as K08 and K23.
R21 Exploratory/Developmental Grant is a grant from the National Institutes of Health (NIH) that funds early-stage, high-risk research projects across biomedical and behavioral science categorical program areas. Awards support projects of up to two years with a maximum of $275,000 in total direct costs, with no more than $200,000 in any single year. Preliminary data are not required for most opportunities. Research strategies may not exceed six pages. Multiple NIH institutes and centers participate, and investigators should consult NIH scientific staff during concept development to confirm that the R21 mechanism is appropriate for their project.
NIBIB Trailblazer Award for New and Early Stage Investigators (R21) is a grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH that funds high-risk, high-impact research at the intersection of engineering, physical sciences, and biomedical sciences. Eligible applicants are NIH-defined New or Early Stage Investigators who have not previously submitted R01 or R15 applications. Awards provide $400,000 in direct costs over three years. No preliminary data are required — projects should be exploratory, novel, and non-incremental. Applications are due June 16, 2026.
Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) is sponsored by National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH). This R03 grant supports pilot projects that investigate understudied proteins associated with rare diseases. Leukodystrophies are rare diseases, and research into the proteins involved in their pathogenesis would be highly relevant.
NCATS program (PAR-25-157) supporting development of innovative technologies for translational science including AI/ML-driven drug discovery, high-throughput screening automation, computational target identification, and novel assay platforms. Funds exploratory research that creates new tools, methods, and technologies to overcome specific translational bottlenecks in the drug development pipeline. Part of NCATS' broader mission that has enabled over 45 promising new drugs to move into clinical trials through partnerships with academia, industry, and patient advocacy groups. NCATS maintains a pharmaceutical collection of nearly every human-approved drug and automated solutions for rapid drug repurposing screening including for emerging infectious diseases.
New Generation of Glucose Control Technologies Incorporating AI/ML is a funding announcement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at NIH that will solicit applications for research to improve open- and closed-loop diabetes control systems for Type 1 diabetes. Research priorities include innovations in analyte sensing, novel hormone formulation and delivery, AI and machine learning-driven algorithms, and digital twin modeling to enhance glycemic control and quality of life. Awards will use the R01 research project grant activity code. Applications are not yet being solicited but the notice was issued to allow potential applicants time to develop meaningful collaborations. Eligible applicants include universities, nonprofits, Tribal governments, for-profit organizations, and federal agencies.
Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) is sponsored by National Center for Advancing Translational Sciences (NCATS) / NIH. This program supports early-stage proof of concept and exploratory technology development for high-risk, high-reward projects that can transform or significantly improve the efficiency of therapeutic development.
Use our free grant finder to search active federal funding opportunities by agency, eligibility, and deadline.
Get a free Grant Score and see how well your organization matches grants like this one.
NIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read articleNIH committed $402 million across 601 multiyear-funded grants in the first eight months of FY 2026 — more than four times the pace of two years ago. The mechanism front-loads obligations into a single fiscal year, leaving less budget for new project starts and squeezing FY 2026 success rates. What researchers and institutions should be doing now.
Read articlePAR-26-042 funds NLM-priority clinical informatics R01 grants up to $250,000 in direct costs per year through March 6, 2029, with standard NIH cycles on October 5, February 5, and June 5. The notice explicitly defines non-responsive applications: incremental tool improvements, projects primarily focused on social determinants of health, and projects primarily focused on ethical/legal/social issues. With NIH SBIR/STTR just reopened and the OMB Uniform Grants Regulation rewrite reshaping discretionary awards, the NLM clinical informatics line is one of the few stable, well-defined biomedical funding streams left at the agency. Here is how to read it.
Read articleThe April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read articleNIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read articleNIH posted PAR-27-032 — Maximizing Investigators' Research Award for Early Stage Investigators — on May 12 as the first NOFO under the HHS SimplerNOFO initiative. Plain language, checklists, restructured sections, and explicit guidance replace the dense traditional NIH announcement. What the redesign means for grant writing strategy across HHS and which NOFOs are next in line.
Read article